Impact of Exclusive Hospital Distribution of Biosimilar on Drug Health Care Budget
2013 Value in health
Remuzat, C. | Vataire, A.L. | Cetinsoy, L. | Aballea, S. | Toumi, M. |
There is an increased trend in shifting biologics distribution to exclusive hospital pharmacy channel. Although it looks obvious that such process will generate savings through tenders at regional or national level such policy consequences were not clearly quantified. We used a model developed for EU commission to assess the consequences of such policies on biosimilars for selected EU countries (model developed for the European Commission for the project”EU Pharmaceutical expenditure forecast” http://ec.europa.eu/health/healthcare/key_documents/index.en.htm).